Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified. Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection. Investigators will dynamically monitor the CMV-specific cellular immune reconstitution after HSCT，and analyze the clinical factors and therapy strategies affecting recovery of CMV-specific immunity during 1 year after HSCT.
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality after hematopoietic stem cell transplantation (HSCT). The course and outcome of CMV infection are different clinically, and the mechanism of CMV infection after transplantation has not been clarified. Reconstitution of cellular immunity after HSCT is a critical determinant of the control of CMV infection. Investigators will collect peripheral blood at 1 month, 2 month, 3 month, and 6 month after HSCT from the participated patients, and dynamically monitor the CMV-specific T and NK cellular immune reconstitution. Investigators will also analyze the clinical factors and therapy strategies affecting recovery of CMV-specific immunity during 1 year after HSCT.
Study Type
OBSERVATIONAL
Enrollment
120
Patients received letermovir as prophylaxis or received preemptive therapy for CMV depends on clinical needs and patients' wishes
Department of Hematology, Peking University People's Hospital
Beijing, Beijing Municipality, China
People's Hospital of Peking University
Beijing, China
Incidence of clinically significant CMV infection (CSI)
Clinically significant CMV infection (CSI) is defined as the administration of antiviral therapy as preemptive therapy for CMV DNAemia or treatment for CMV disease.
Time frame: 6 months after HSCT
Incidence of refractory CMV infection and CMV disease
Refractory CMV infection is defined as a persistent viral load (CMV viral load at the same level or higher than the peak viral load within 1 week but \<1 log10 increase in CMV DNA titers done in the same laboratory and with the same assay) after at least 2 weeks of appropriately dosed antiviral therapy.
Time frame: 6 months after HSCT
Numbers of immune cells in peripheral blood
PBMCs from HSCT recipients were collected at 1 month, 2 month, 3 month, and 6 month after HSCT, and tested for NK cells, T cells, CMV-specific T cells and their subsets.
Time frame: 6 months after HSCT
Treatment-ralated mortality
Treatment-ralated mortality
Time frame: Through study completion, an average of 1 year
Overall survival
Overall survival
Time frame: Through study completion, an average of 1 year
Incidence of other viral infection and viral-associated disease
Other viral infection and viral-associated diseases including EBV, ADV, HHV-6, BKV and HSV
Time frame: 6 months after HSCT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.